A novel small diameter nanotextile arterial graft is associated with surgical feasibility and safety and increased transmural endothelial ingrowth in pig

Journal of Nanobiotechnology

Raimondo Ascione¹  Nadiah Sulaiman¹  Thomas W. Johnson¹  Sarah Jane George¹  Alexander Ward¹  Vito Domenico Bruno¹  John Joseph²  Helna Mary Baby³  Deepthy Menon³  Shantikumar V. Nair³ 

[1] Bristol Heart Institute and Translational Biomedical Research Centre, Faculty of Health Science, University of Bristol, BS2 8HW, Bristol, UK;Bristol Heart Institute and Translational Biomedical Research Centre, Faculty of Health Science, University of Bristol, BS2 8HW, Bristol, UK;Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, 682 041, Kochi, India;Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, 682 041, Kochi, India;

关键词: Nanotextile;    Small diameter vascular grafts;    Endothelialisation;    Nanofibers;    Electrospinning;    In-vivo feasibility;    Coronary surgery;    Vascular surgery;    Nanotextile vascular prosthesis;    Vascular graft failure;    Tissue engineering;   

DOI  :  10.1186/s12951-022-01268-1

来源: Springer

【 摘 要 】

Globally, millions of patients are affected by myocardial infarction or lower limb gangrene/amputation due to atherosclerosis. Available surgical treatment based on vein and synthetic grafts provides sub-optimal benefits. We engineered a highly flexible and mechanically robust nanotextile-based vascular graft (NanoGraft) by interweaving nanofibrous threads of poly-L-lactic acid to address the unmet need. The NanoGrafts were rendered impervious with selective fibrin deposition in the micropores by pre-clotting. The pre-clotted NanoGrafts (4 mm diameter) and ePTFE were implanted in a porcine carotid artery replacement model. The fibrin-laden porous milieu facilitated rapid endothelization by the transmural angiogenesis in the NanoGraft. In-vivo patency of NanoGrafts was 100% at 2- and 4-weeks, with no changes over time in lumen size, flow velocities, and minimal foreign-body inflammatory reaction. However, the patency of ePTFE at 2-week was 66% and showed marked infiltration, neointimal thickening, and poor host tissue integration. The study demonstrates the in-vivo feasibility and safety of a thin-layered vascular prosthesis, viz., NanoGraft, and its potential superiority over the commercial ePTFE.Graphical Abstract

【 授权许可】

CC BY